Vol. 52 (2023): Supplement: Mineralocorticoid antagonists in the cardio-renal-metabolic continuum: emerging role of finerenone

Review Article

• Preface

  Eduardo R Perna, Daniel Piskorz

  4

  • PDF (Spanish)

• Comparative pharmacological profile and cardiovascular impact of classic and emergent mineralocorticoid antagonist receptors

  Felipe Martinez, Eduardo R Perna, Daniel Piskorz

  5-14

  • PDF (Spanish)

• Finerenone: trayectory from the evidence to standard use en patients with diabetes and renal disease

  Daniela García Brasca, Sergio Gimenez, Nicolás Renna, Marcelo Orias

  15-20

  • PDF (Spanish)